Comment on Nuño Solinís R, et al. 'Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic Evidence'

Autor: Patrice Cacoub
Přispěvatelé: Immunologie - Immunopathologie - Immunothérapie (I3), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service de Département de médecine interne et immunologie clinique [CHU Pitié-Salpêtrière] (DMIIC), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), HAL-UPMC, Gestionnaire, Service de médecine interne et d'immunologie clinique [CHU Pitié-Salpêtrière], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
Jazyk: angličtina
Rok vydání: 2017
Předmět:
0301 basic medicine
Microbiology (medical)
medicine.medical_specialty
Letter
03 medical and health sciences
0302 clinical medicine
Chronic hepatitis
[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases
Medicine
Intensive care medicine
business.industry
virus diseases
Fibrosis stage
[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology
medicine.disease
Virology
Cryoglobulinemia
digestive system diseases
[SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology
3. Good health
030104 developmental biology
Infectious Diseases
Mixed cryoglobulinemia
[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases
030211 gastroenterology & hepatology
business
Economic evidence
Zdroj: Infectious Diseases and Therapy
Infectious Diseases and Therapy, 2017, 6 (2), pp.297-301. ⟨10.1007/s40121-017-0155-0⟩
Infectious Diseases and Therapy, Springer Verlag, 2017, 6 (2), pp.297-301. ⟨10.1007/s40121-017-0155-0⟩
ISSN: 2193-8229
2193-6382
DOI: 10.1007/s40121-017-0155-0⟩
Popis: International audience; As demonstrated in the review by Nuño Solinís et al. [4], we now have highly effective, well-tolerated, and cost-effective therapies to treat essentially anyone who is infected with HCV. With these tools, we can prevent not only hepatic but also many extrahepatic diseases caused by HCV. As such, I believe that interferon-free DAA therapy should be offered to most patients that have HCV EHMs as well as to all patients at risk of developing them. This stands out as the best approach to deal with the serious complications of chronic HCV infection and to speed the way to a world in which HCV is effectively eradicated.
Databáze: OpenAIRE
Externí odkaz: